AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...
For AbbVie, (NYSE: ABBV) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years. Here's how this drugmaker proved the bears ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback